Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Complementary Medicine and Therapies
Published in: BMC Complementary Medicine and Therapies 1/2023

Open Access 01-12-2023 | Respiratory Microbiota | Research

Gut microbiota combined with fecal metabolomics reveals the effects of FuFang Runzaoling on the microbial and metabolic profiles in NOD mouse model of Sjögren’s syndrome

Authors: Changming Chen, Ping Zeng, Xueming Yao, Zhaowei Huang, Yi Ling, Ying Huang, Lei Hou, Hufan Li, Dan Zhu, Wukai Ma

Published in: BMC Complementary Medicine and Therapies | Issue 1/2023

Login to get access

Abstract

Objective

Sjögren’s syndrome (SS) is an inflammatory autoimmune disease characterized by high levels of chronic lymphocyte infiltration. Differences and dysfunction in the gut microbiota and metabolites may be closely related to the pathogenesis of SS. The purpose of this study was to reveal the relationship between the gut microbiota and metabolome in NOD mice as a model of SS and the role of FuFang Runzaoling (FRZ), which is a clinically effective in treating SS.

Methods

NOD mice were gavaged with FRZ for 10 weeks. The ingested volume of drinking water, submandibular gland index, pathologic changes of the submandibular glands, and serum cytokines interleukin (IL)-6, IL-10, IL-17 A, and tumor necrosis factor-alpha (TNF-α) were determined. The roles of FRZ on gut microbiota and fecal metabolites were explored by 16 S rRNA gene sequencing and liquid chromatography-mass spectrometry (LC-MC), respectively. The correlation between them was determined by Pearson correlation analysis.

Results

Compared with the model group, the drinking water volume of NOD mice treated with FRZ increased and the submandibular gland index decreased. FRZ effectively ameliorated lymphocyte infiltration in the small submandibular glands in mice. Serum levels of IL-6, TNF-α, and IL-17 A decreased, and IL-10 increased. The Firmicutes/Bacteroidetes ratio in the FRZ treatment group was higher. FRZ significantly downregulated the relative abundance of the family Bacteroidaceae and genus Bacteroides, and significantly upregulated the relative abundance of genus Lachnospiraceae_UCG-001. Orthogonal projections to latent structures discriminant analysis (OPLS-DA) revealed the significant change in fecal metabolites after FRZ treatment. Based on criteria of OPLS-DA variable influence on projection > 1, P < 0.05, and fragmentation score > 50, a total of 109 metabolites in the FRZ-H group were differentially regulated (47 downregulated and 62 upregulated) compared to their expressions in the model group. Kyoto Encyclopedia of Genes and Genomes pathway analysis revealed enriched metabolic of sphingolipid metabolism, retrograde endocannabinoid signaling, GABAergic synapse, necroptosis, arginine biosynthesis, and metabolism of histidine, alanine, aspartate, and glutamate. Correlation analysis between gut microbiota and fecal metabolites suggested that the enriched bacteria were related to many key metabolites.

Conclusions

Taken together, we found FRZ could reduce the inflammatory responses in NOD mice by regulating the gut microbiota, fecal metabolites, and their correlation to emerge a therapeutic effect on mice with SS. This will lay the foundation for the further studies and applications of FRZ, and the use of gut microbiotas as drug targets to treat SS.

Graphical Abstract

Appendix
Available only for authorised users
Literature
1.
Negrini S, Emmi G, Greco M, Borro M, Sardanelli F, Murdaca G, Indiveri F, Puppo F. Sjögren’s syndrome: a systemic autoimmune disease. Clin Exp Med. 2022;22(1):9–25PubMedCrossRef
2.
Bjordal O, Norheim KB, Rødahl E, Jonsson R, Omdal R. Primary Sjögren’s syndrome and the eye. Surv Ophthalmol. 2020;65(2):119–32PubMedCrossRef
3.
4.
Trujillo-Vargas CM, Schaefer L, Alam J, Pflugfelder SC, Britton RA, de Paiva CS. The gut-eye-lacrimal gland-microbiome axis in Sjögren Syndrome. Ocul Surf 2020;18(2):335–44PubMedCrossRef
5.
Zhao L, Dong M, Liao S, Du Y, Zhou Q, Zheng H, Chen M, Ji J, Gao H. Identification of key metabolic changes in renal interstitial fibrosis rats using metabonomics and pharmacology. Sci Rep. 2016;6:27194PubMedPubMedCentralCrossRef
6.
Luan H, Wang X, Cai Z. Mass spectrometry-based metabolomics: targeting the crosstalk between gut microbiota and brain in neurodegenerative disorders. Mass Spectrom Rev. 2019;38(1):22–33PubMedCrossRef
7.
Yuan X, Hou L, Zeng P, Ma W. Clinical observation on 30 cases of Sjogren’s syndrome treated by runzaoling decoction. J Guiyang Coll Tradit Chin Med. 2018;40(2):43–5.
8.
Ma W, Zhong Q, Yao X, Liu Z, Tang F, An Y, Huang Y. Clinical observation on therapeutic effect of Miao traditional medicine Jinwujiangu Decoction on rheumatoid arthritis. Chin J Tradit Chin Med Pharm. 2010;25(12):2190–2.
9.
Yuan X, Hou L, Zeng P, Ma W. Observation on therapeutic effect of runzaoling for 30 cases of Sjögren’s syndrome. J Guiyang Univ Chin Med. 2018;40(2):43–5.
10.
Zeng P, Jiang Z, Huang Z, Huang Y, Xu H, Chen C, Ma W. PI3K/AKT/mTOR signaling pathway is downregulated by runzaoling (RZL) in Sjögren’s Syndrome. Mediat Inflamm. 2022;2022:7236118CrossRef
11.
Jia E, Liu L, Yao X, Ma W. The influence of runzaoling on AQP1 and AQP5 in submaxillary gland of mice with Sjögren’s syndrome. Int J Trad Chin Med. 2011;33(4):316–8.
12.
Ma W, Zeng P, He X, Ning Q, Yao X, Zhou J. Hou L. Effects of runzaoling recipe on serum Th1/Th2 in Sjögren’s syndrome model mice. J Tradit Chin Med. 2017;58(4):329–33.
13.
Hou L, Zeng P, He X, Ning Q, Yao X, Zhou J, Ma W. Effects of Runzaoling on Th17/Treg cells in Sjögren’s syndrome model mice. Pharmacol Clin o Chin Materia Med. 2017;33(2):158–62.
14.
15.
Ramos-Casals M, Brito-Zerón P, Bombardieri S, Bootsma H, De Vita S, Dörner T, Fisher BA, Gottenberg JE, Hernandez-Molina G, Kocher A, et al. EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies. Ann Rheum Dis. 2020;79(1):3–18PubMedCrossRef
16.
Lin X, Rui K, Deng J, Tian J, Wang X, Wang S, Ko KH, Jiao Z, Chan VS, Lau CS, et al. Th17 cells play a critical role in the development of experimental Sjögren’s syndrome. Ann Rheum Dis. 2015;74(6):1302–10PubMedCrossRef
17.
Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2023;51(D1):D587–d592PubMedCrossRef
18.
19.
Stefanski AL, Tomiak C, Pleyer U, Dietrich T, Burmester GR, Dörner T. The diagnosis and treatment of Sjögren’s Syndrome. Deutsches Arzteblatt Int. 2017;114(20):354–61.
20.
Ramos-Casals M, Brito-Zerón P, Sisó-Almirall A, Bosch X, Tzioufas AG. Topical and systemic medications for the treatment of primary Sjögren’s syndrome. Nat Rev Rheumatol. 2012;8(7):399–411PubMedCrossRef
21.
Ma W, Zeng P, He X, Ning Q, Zhou J, Hou L. Study on Chinese medicine Runzaoling to submandibular gland of Sjögren’s syndrome model mice. Chin Archives Traditional Chin Med. 2017;35(11):2912–4.
22.
Zhong D, Wu C, Zeng X, Wang Q. The role of gut microbiota in the pathogenesis of rheumatic diseases. Clin Rheumatol. 2018;37(1):25–34PubMedCrossRef
23.
Tsigalou C, Stavropoulou E, Bezirtzoglou E. Current insights in Microbiome Shifts in Sjogren’s syndrome and possible therapeutic interventions. Front Immunol. 2018;9:1106PubMedPubMedCentralCrossRef
24.
Brandsma E, Kloosterhuis NJ, Koster M, Dekker DC, Gijbels MJJ, van der Velden S, Ríos-Morales M, van Faassen MJR, Loreti MG, de Bruin A, et al. A proinflammatory gut microbiota increases systemic inflammation and accelerates atherosclerosis. Circul Res. 2019;124(1):94–100CrossRef
25.
26.
de Paiva CS, Jones DB, Stern ME, Bian F, Moore QL, Corbiere S, Streckfus CF, Hutchinson DS, Ajami NJ, Petrosino JF, et al. Altered mucosal microbiome diversity and disease severity in Sjögren syndrome. Sci Rep. 2016;6:23561PubMedPubMedCentralCrossRef
27.
Mandl T, Marsal J, Olsson P, Ohlsson B, Andréasson K. Severe intestinal dysbiosis is prevalent in primary Sjögren’s syndrome and is associated with systemic disease activity. Arthritis Res therapy. 2017;19(1):237CrossRef
28.
Bellocchi C, Fernández-Ochoa Á, Montanelli G, Vigone B, Santaniello A, Milani C, Quirantes-Piné R, Borrás-Linares I, Ventura M, Segura-Carrettero A, et al. Microbial and metabolic multi-omic correlations in systemic sclerosis patients. Ann N Y Acad Sci. 2018;1421(1):97–109PubMedCrossRef
29.
Mendez R, Watane A, Farhangi M, Cavuoto KM, Leith T, Budree S, Galor A, Banerjee S. Gut microbial dysbiosis in individuals with Sjögren’s syndrome. Microb Cell Fact. 2020;19(1):90PubMedPubMedCentralCrossRef
30.
de Souza TR, de Albuquerque Tavares Carvalho A, Duarte ÂP, Porter SR, Leão JC, Gueiros LA. Th1 and Th2 polymorphisms in Sjögren’s syndrome and rheumatoid arthritis. J oral Pathol Med: Public Int Assoc Oral Pathol Am Acad Oral Pathol. 2014;43(6):418–26CrossRef
31.
Saraiva M, Vieira P, O’Garra A. Biology and therapeutic potential of interleukin-10. J Exp Med. 2020;217(1):e20190418PubMedCrossRef
32.
Qi J, Li D, Shi G, Zhang X, Pan Y, Dou H, Wang T, Yao G, Hou Y. Interleukin–12 exacerbates Sjögren’s syndrome through induction of myeloid–derived suppressor cells. Mol Med Rep. 2019;20(2):1131–8PubMedPubMedCentral
33.
Kim DS, Woo JS, Min HK, Choi JW, Moon JH, Park MJ, Kwok SK, Park SH, Cho ML. Short-chain fatty acid butyrate induces IL-10-producing B cells by regulating circadian-clock-related genes to ameliorate Sjögren’s syndrome. J Autoimmun. 2021;119:102611PubMedCrossRef
34.
Goto Y, Panea C, Nakato G, Cebula A, Lee C, Diez MG, Laufer TM, Ignatowicz L. Ivanov, II: segmented filamentous bacteria antigens presented by intestinal dendritic cells drive mucosal Th17 cell differentiation. Immunity. 2014;40(4):594–607PubMedPubMedCentralCrossRef
35.
De Paiva CS, Chotikavanich S, Pangelinan SB, Pitcher JD 3rd, Fang B, Zheng X, Ma P, Farley WJ, Siemasko KF, Niederkorn JY, et al. IL-17 disrupts corneal barrier following desiccating stress. Mucosal Immunol. 2009;2(3):243–53PubMedPubMedCentralCrossRef
36.
Hevia A, Milani C, López P, Cuervo A, Arboleya S, Duranti S, Turroni F, González S, Suárez A, Gueimonde M, et al. Intestinal dysbiosis associated with systemic lupus erythematosus. mBio. 2014;5(5):e01548–01514PubMedPubMedCentralCrossRef
37.
Zhang X, Zhang D, Jia H, Feng Q, Wang D, Liang D, Wu X, Li J, Tang L, Li Y, et al. The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. Nat Med. 2015;21(8):895–905PubMedCrossRef
38.
Meehan CJ, Beiko RG. A phylogenomic view of ecological specialization in the Lachnospiraceae, a family of digestive tract-associated bacteria. Genome Biol Evol. 2014;6(3):703–13PubMedPubMedCentralCrossRef
39.
Huang G, Zhang S, Zhou C, Tang X, Li C, Wang C, Tang X, Suo J, Jia Y, El-Ashram S, et al. Influence of Eimeria falciformis infection on gut microbiota and metabolic pathways in mice. Infect Immun. 2018;86(5):e00073PubMedPubMedCentralCrossRef
40.
Ceccarani C, Bassanini G, Montanari C, Casiraghi MC, Ottaviano E, Morace G, Biasucci G, Paci S, Borghi E, Verduci E. Proteobacteria overgrowth and butyrate-producing taxa depletion in the gut microbiota of glycogen storage disease type 1 patients. Metabolites. 2020;10(4):133PubMedPubMedCentralCrossRef
41.
Yang M, Gu Y, Li L, Liu T, Song X, Sun Y, Cao X, Wang B, Jiang K, Cao H. Bile acid-gut microbiota axis in inflammatory bowel disease: from bench to bedside. Nutrients. 2021;13(9):3143.PubMedPubMedCentralCrossRef
42.
43.
Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol. 2008;9(2):139–50PubMedCrossRef
44.
45.
Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G, Aradhye S, Burtin P. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discovery. 2010;9(11):883–97PubMedCrossRef
46.
Zhang MM, Jiang YS, Lv HC, Mu HB, Li J, Shang ZW, Zhang RJ. Pathway-based association analysis of two genome-wide screening data identifies rheumatoid arthritis-related pathways. Genes Immun. 2014;15(7):487–94PubMedCrossRef
47.
Zheng Z, Zhang X, Liu J, He P, Zhang S, Zhang Y, Gao J, Yang S, Kang N, Afridi MI, et al. GABAergic synapses suppress intestinal innate immunity via insulin signaling in Caenorhabditis elegans. Proc Natl Acad Sci USA. 2021;118(20):e2021063118PubMedPubMedCentralCrossRef
48.
Zhao J, Jiang P, Guo S, Schrodi SJ, He D. Apoptosis, autophagy, NETosis, necroptosis, and pyroptosis mediated programmed cell death as targets for innovative therapy in rheumatoid arthritis. Front Immunol. 2021;12:809806PubMedPubMedCentralCrossRef
49.
Cho YS, Challa S, Moquin D, Genga R, Ray TD, Guildford M, Chan FK. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell. 2009;137(6):1112–23PubMedPubMedCentralCrossRef
50.
Nascimento MM, Alvarez AJ, Huang X, Browngardt C, Jenkins R, Sinhoreti MC, Ribeiro APD, Dilbone DA, Richards VP, Garrett TJ, et al. Metabolic profile of Supragingival plaque exposed to arginine and fluoride. J Dent Res. 2019;98(11):1245–52PubMedPubMedCentralCrossRef
51.
52.
Uemura T, Suzuki T, Saiki R, Dohmae N, Ito S, Takahashi H, Toida T, Kashiwagi K, Igarashi K. Activation of MMP-9 activity by acrolein in saliva from patients with primary Sjögren’s syndrome and its mechanism. Int J Biochem Cell Biol. 2017;88:84–91PubMedCrossRef
53.
Xu T, Guo Y, Lu J, Shan J, Lin L, Qian W, Chen W, Wang J, Lv X, Ke M, et al. Untargeted serum metabolomics and potential biomarkers for Sjögren’s syndrome. Clin Exp Rheumatol. 2021;39(Suppl 133):23–9PubMedCrossRef
Metadata
Title
Gut microbiota combined with fecal metabolomics reveals the effects of FuFang Runzaoling on the microbial and metabolic profiles in NOD mouse model of Sjögren’s syndrome
Authors
Changming Chen
Ping Zeng
Xueming Yao
Zhaowei Huang
Yi Ling
Ying Huang
Lei Hou
Hufan Li
Dan Zhu
Wukai Ma
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2023
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-023-04017-5

Other articles of this Issue 1/2023

BMC Complementary Medicine and Therapies 1/2023 Go to the issue

Correction

Correction: Traditional medicine users in a treated chronic disease population: a cross-sectional study in Indonesia

Study Protocol

Effectiveness of an amygdala and insula retraining program combined with mindfulness training to improve the quality of life in patients with long COVID: a randomized controlled trial protocol

Research

Combinative effects of akarkara root-derived metabolites on anti-inflammatory and anti-alzheimer key enzymes: integrating bioassay-guided fractionation, GC-MS analysis, and in silico studies

Research

The potential effect and mechanism of Saikosaponin A against gastric cancer

Research

Anti-proliferative activity of Artemisia marschalliana on cancerous cell lines

Research

Shaoyao decoction alleviates TNBS-induced ulcerative colitis by decreasing inflammation and balancing the homeostasis of Th17/Treg cells